News
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...
Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & ...
Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback